Information Provided By:
Fly News Breaks for May 22, 2017
PBYI
May 22, 2017 | 13:15 EDT
JPMorgan analyst Cory Kasimov is "incrementally more positive" on Puma Biotechnology ahead of Wednesday's FDA advisory panel. The analyst has an Overweight rating on the shares with an $89 price target. The tone and content of the documents are supportive of neratinib, Kasimov tells investors in a research note. The analyst says he's not overly concerned by the disclosure that the FDA advised Puma not to file in March 2016, since the meeting prompted a number of follow-up sensitivity analyses.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.